看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
. X" a" S% d" B1 {' g, A/ t9 u" [( _: S$ w2 v1 y
9 P6 ~2 }% z b, qCurrently available feasibility data for possible combination strategies.
1 v) C9 y9 j% y; _————————————————————————————————, r0 N' u) t& a' R' e$ i# n9 K
Combination Feasibility according to preliminary data
8 v" w& o. e7 K: m1 ?& D——————————————————————————————————' M+ ]5 P; s# B* H' v0 x
Bevacizumab + sorafenib Yes, reduced dose 0 l) \! g* Z, F9 [
Bevacizumab + sunitinib† No
% I- y8 H. I* X4 d0 I' Y4 `Bevacizumab + temsirolimus Yes
7 L! Q& z: W7 B/ |Bevacizumab + everolimus Yes
. ~1 V) F" d1 VSorafenib + sunitinib ?
5 X& z# t0 x9 c2 ?0 m. f. M& [Sorafenib + temsirolimus Yes, reduced dose
( l; |) u) Q" h l4 V$ t& @8 ESorafenib + everolimus Yes, reduced dose 9 z- R8 f; ^+ s$ ?4 W2 Z
Sunitinib + temsirolimus† No 3 `* f8 Q" _2 [. g1 ?1 B
Sunitinib + everolimus ?
' W6 c6 i: L+ }( F3 [3 @Temsirolimus + everolimus ?
0 K3 N- @1 t2 F1 x3 j' U————————————————————
" e. s- q% I& k! D/ |†Led to US FDA warning.
! x3 W+ L/ J. m% [8 f) l7 F5 z?: As yet unattempted combination.; m2 A' g+ |. Y
|